From September 6 to 11, 2026, the European Peptide Symposium (EPS 2026) brought together leading scientists, researchers, and industry professionals at the University of Vienna in Austria. As one of Europe’s leading scientific gatherings for peptide research, the symposium provided an important platform for scientific exchange and collaboration across the global peptide community.

The JYMed Peptide European Business Team was on site at Booth SE04, showcasing our end-to-end CRDMO capabilities spanning drug discovery, process development, and commercial-scale manufacturing.

Throughout the symposium, Prof. Fernando Albericio, Chief Scientific Advisor at JYMed Peptide, and Dr. Beatriz G. de la Torre, Principal Scientific Advisor, joined our European team at the booth while participating in the scientific program, engaging with researchers and industry professionals from around the world.

Discussions covered key industry topics including peptide API regulatory filings, CDMO process development, scale-up and commercial manufacturing, GLP-1 peptides, and peptide-drug conjugates (PDCs).

Drawing on their extensive academic and industry experience in peptide medicinal chemistry, synthetic process development, and complex peptide route optimization, Prof. Albericio and Dr. de la Torre engaged in in-depth scientific discussions with researchers and industry peers throughout the event, bringing valuable scientific perspectives to the conversations taking place at the JYMed booth.

End-to-End CRDMO Services

A comprehensive R&D and manufacturing platform covering the entire journey from drug discovery through commercial production, enabling seamless transitions across each stage of peptide development.

Robust Regulatory Support

Supported by internationally recognized regulatory experience, quality systems, and certifications, JYMed Peptide serves global markets under standards and frameworks including NMPA, FDA, EDQM, GMP, ISO, and HALAL.

Comprehensive Peptide API Portfolio

A diverse portfolio of more than 20 peptide APIs, including semaglutide and liraglutide, alongside peptide conjugates and complex modified peptides.

JYMed Peptide

EPS 2026 has officially come to a close!

Our time in Vienna was an important opportunity to showcase JYMed Peptide’s scientific and technical capabilities on an international stage, while strengthening connections with researchers, partners, and industry peers across the global peptide community.

Looking ahead, JYMed Peptide will continue advancing its capabilities in complex peptides, innovative peptide therapeutics, and advanced synthesis and process development. By addressing increasingly complex technical challenges and strengthening our development and manufacturing platforms, we aim to provide global partners with reliable, scalable peptide solutions and contribute to the continued advancement of peptide therapeutics worldwide.